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Memantine prodrug as a new agent 
for Alzheimer’s Disease
simona sestito1, simona Daniele1, Deborah pietrobono1, Valentina Citi1, Lorenza Bellusci2, 
Grazia Chiellini2, Vincenzo Calderone1,3, Claudia Martini1 & simona Rapposelli  1,3
Hydrogen sulphide has recently drawn much attention due to its potent anti-inflammatory and 
neuroprotective roles in brain functions. The purpose of the current study was to exploit these beneficial 
properties of H2s to design a new agent for the treatment of Alzheimer’s disease (AD). to pursue our 
aims, we replaced the free amine group of memantine with an isothiocyanate functionality as a putative 
H2s-donor moiety. the new chemical entity, named memit, was then tested in vitro to determine 
whether it retains the pharmacological profile of the “native drug”, while also providing a source of H2s 
in the CNs. Indeed, Memit showed the ability to release H2s through a cysteine-mediated mechanism, 
thus generating memantine. Moreover, the new hybrid molecule exerts protective effects against 
neuronal inflammation and induces a drastic fall in ROS production. In addition, memit was also able to 
reduce the Aβ(1-42) self-induced aggregation and exerted cytoprotective effect against Aβ oligomers-
induced damage in both human neurons and rat microglia cells. Finally, similarly to memantine, the 
new compound promotes autophagy, a complex process required for cellular homeostasis in cell 
survival that results to be altered in neurodegenerative diseases. In conclusion, our study revealed 
that memit is a prodrug of memantine. Further in vivo studies will be necessary to fully investigate the 
synergic or cumulative effects due to the H2s-releasing moiety and the native drug.
Alzheimer’s disease (AD) is a progressive age-dependent neurodegenerative brain disorder that slowly destroys 
memory and thinking skills. It is the cause of 60% to 70% of cases of dementia and represent one of the main 
public health issue with a significant impact on the whole society.
Over the past two decades, it has become increasingly apparent that AD neuropathology is characterized by 
a dramatic reduction of H2S production in the CNS1. H2S is a gaseous transmitter that functions as a smooth 
muscle relaxant and neuromodulator. It is produced endogenously from the amino acids L-cysteine and homo-
cysteine (HCy) by several enzymes such as cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 
3-mercaptopyruvate sulfurtransferase (3MST) along with cysteine aminotransferase (CAT).
CBS, highly expressed in the hippocampus and cerebellum, is the main enzyme responsible for the pro-
duction of H2S in the brain2. Following a neuronal excitation, CBS produces H2S which enhances the NMDA 
receptor-mediated responses thus affecting memory and facilitating the induction of long-term potentiation 
(LTP)3. Recently, a dramatic decrease of CBS activity and consequently a drastic fall in H2S levels (about 50%) 
have been detected in the brain of patients affected by AD, thus suggesting that a reduced production of H2S may 
be involved in the cognitive decline associated to AD4.
Nowadays, H2S is also considered a neuromodulator2,5 since it interacts with N-methyl-D-aspartate (NMDA), 
a class of ionotropic glutamate receptors which play critical roles in synaptic plasticity. Even though the mech-
anism is not yet completely understood, H2S seems to interact with NMDA receptor both directly, through the 
sulfhydration of cysteine residues6, and indirectly, by regulating the level of intracellular Ca2+ 7.
Several in vitro and in vivo experiments have shown the neuroprotective role of H2S in AD8–11. Growing evi-
dences indicate that NaHS, an exogenous H2S-generating agent, induces neuroprotection against oxidative stress 
(OS) through at least three main mechanisms: (a) restoration of GSH (glutathione) cellular levels12; (b) activation 
of ATP sensitive potassium channels (KATP); (c) reduction of mitochondrial ROS production13,14. Recently, it has 
been also demonstrated that H2S has protective effects against Aβ-induced cell injury by inhibiting inflammation, 
promoting cell growth, and preserving mitochondrial function2,15.
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In addition, H2S exhibits anti-inflammatory and antiapoptotic activities. Indeed, administration of NaHS 
in a rat model of AD proved to dramatically reduce the release of proinflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin IL-1β and IL-6 induced by amyloid β-peptides. Moreover, it inhibits the 
upregulation of COX2 enzyme and the activation of the nuclear factor-κB (NF-kβ) in the hippocampus16, thus 
reiterating the high potential value of H2S in AD therapy. Further H2S neuroprotective mechanisms have been 
suggested: such as the reduction of lipopolysaccharide (LPS)-induced NO production in microglia via inhibition 
of p38-MAPK pathway17.
Taken together all these findings corroborate the functional involvement of H2S in neurodegenerative dis-
eases18. Therefore, the restoration of the correct levels of endogenous H2S is an appealing novel approach for 
the development of new pharmacological therapies for AD, that are still lacking of an effective treatment. In this 
paper we decide to investigate the possibility to exploit the H2S properties to design a new agent for the treatment 
of AD, following the multitarget directed ligand strategy (MTDL). This approach is currently used for the design 
of new molecules to be used in several multifactorial pathologies such as cancer19, cardiovascular20 and neurode-
generative diseases, including AD21,22.
Even though the combination of two or more pharmacophores into a single molecule has been extensively 
studied, the introduction of an H2S-donor moiety into the molecular scaffold of a “native” neuroprotective drug 
has not been explored yet9,23–25. Consistently, to pursue our aim we selected memantine as “native drug” to com-
bine appropriately with a H2S-generating moiety. Memantine is an excellent example of neuroprotective drug. It 
is a well-known uncompetitive voltage-dependent NMDA receptor antagonist, targeting principally NMDAR 
pathological hyperfunction26, and approved in 2003 by FDA as a treatment option for moderate to severe AD.
Starting from memantine, we replaced the free amine group with an isothiocyanate functionality as a putative 
H2S-donor moiety (Fig. 1). Indeed, recent studies showed that both synthetic and naturally occurring isothiocy-
anates generate H2S with a slow releasing rate27,28. Increasing studies have shown that H2S-generating agents for 
clinical use should retain some requirements such as a slow releasing rate, low and long-lasting concentration and 
favorable pharmacokinetics29,30. All these features are essential to take full advantage of the beneficial effects of 
H2S, thus avoiding the onset of toxicity.
Accordingly, a slow–releasing H2S donor memantine-like molecule, namely Memit, was developed and its 
neuroprotective properties were investigated in human neuronal-like cells.
Methods
Chemical synthesis. Commercial grade anhydrous solvents were used without further drying. 
Commercially available chemicals were purchased from Sigma Aldrich and used without further purification. 
Evaporation was performed in vacuum (rotating evaporator). Anhydrous Na2SO4 was used as the drying agent. 
Flash chromatography was performed on Merck 60 Å high-purity grade silica gel (0.40–63 μm). Reaction was 
followed by TLC, performed on Merck aluminum silica gel (60 F254) sheets. Spots were viewed under a UV 
lamp (254 nm). 1H and 13C NMR spectra were obtained using a Bruker Avance 400 spectrometer and were 
recorder at 400, and 101 MHz, respectively. Chemical shifts are reported in parts per million (ppm) d values, 
coupling constants J are reported in hertz (Hz). Data for 1H NMR spectra are reported as follows: chemical 
shift (δ ppm), multiplicity, integration, coupling constant (Hz). Multiplicities are reported as follows: s = singlet, 
m = multiplet. Synthesis of memit was reported in Fig. 1. Briefly, to a stirred solution of Memantine (300 mg, 
mmol 1.67) in DCM (15 ml) and NaHCO3 6% (15 ml) cooled at 0 °C, was added dropwise thiophosgene (1.28 ml, 
16.7 mmol). The resulting mixture was stirred at 2 h at r.t, followed by TLC, then the aqueous phase was sepa-
rated and extracted several times with DCM, dried over anhydrous Na2SO4 and concentrated. The crude product 
was purified through flash chromatography (AcOEt/n-hexane 9:1 as the eluent) to get Memit as a clear oil31. 1H 
NMR (CDCl3–400 MHz): δ 0.84 (s, 6H), 1.12 (s, 2H), 1.24–1.34 (s, 4H), 1.47–1.69 (m, 4H), 1.77–1.78 (m, 2H), 
2.11–2.16 (m, 1H) ppm. 13 C NMR (CDCl3–400 MHz): 129.96 (NCS); 59.71; 49.84; 49.59; 42.24; 42.03; 41.85; 
32.78; 32.55; 28.86; 28.75; 29.64.
Cell cultures differentiation into neurons. H9-derived Neural Stem Cells (NSCs) were cultured as 
reported before32,33. Neurobasal serum-free medium with 5 µM retinoic acid was used to differentiate cells into 
neurons32,33.
Cellular model of inflammation and viability/proliferation assays in neuronal-like cells. The 
compounds Memit and Memantine were diluted in DMSO. Neuronal-like cells, differentiated from H9-derived 
were incubated for 16 h with an inflammatory cocktail of LPS and TNF-α (50 ng/ml), as previously reported32. To 
verify the protective effects of Memit and Memantine, neuronal-like cells were treated with the two compounds 
for 24 or 72 h, then the samples were washed and incubated with LPS plus TNF-α for 16 h32 or oligomeric Aβ1–42 
Figure 1. Structures of Memantine and the relative H2S-donor hybrid memit.
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for 24 h. In selected experiments, NaHS was used as a positive control. Following incubation, cell viability was 
determined using the MTS assay32.
Cell proliferation/viability assays on rat microglia cells. Rat microglia cells were isolated from mixed 
cell culture obtained from Sprague-Dawley rat cortex, by gentle physical shaking, as described34,35. After isolation, 
cells were seeded into 96 well-plated with fresh culture media and pretreated with Memit or Memantine (10 µM) 
for 24 h; before washing and incubation with oligomeric Aβ1–42 for 24 h. Following incubation time, cell viability 
was determined using the MTS assay32.
Ros production. ROS activity within the cells was determined using the fluorogenic dye 
2′,7′-dichlorofluorescin diacetate (H2DCFDA, Molecular Probes, Invitrogen). NSCs were seeded in black 
96-multiwell plates (5 × 103 cells/well). The cells were treated with Memit or Memantine at the concentration 
of 10 µM for 24 h; after the incubation time, cells were washed and incubated with LPS and TNF-α for 16 h. One 
hour prior to treatment completion, 50 μM H2DCFDA was added to the same media in the dark at 37 °C. As a 
positive control, H2O2 was added at a concentration of 100 μM. The fluorescence intensity (excitation 485 nm and 
emission 520 nm) was normalized based on the number of cells stained with crystal violet36. In selected experi-
ments, NaHS was used as a positive control.
Glioma cell culture and viability experiments. U-87MG cell line was obtained from the National 
Institute for Cancer Research of Genoa (Italy) and cultured as previously described37. The effects of com-
pound treatment on U87MG cell viability were evaluated using the tetrazolium dye (MTT) colorimetric 
assay. Briefly, Memantine (10 μM) or Memit (10 μM) was added to 96-well plates containing 5,000 U-87MG 
cells/well. After incubation for 24 h, cell growth was measured by MTT (3-(4,5-dimethylthiazolyl-2)-2,-diphe-
nyltetrazoliumbromide) proliferation assay. Absorbance at 570 nm was measured using a Bio-Rad model 550 
microplate reader (BioRad Molecular Bioscience Group, Hercules, USA). The data represent the means of three 
independent experiments.
Western blot analysis. U-87MG cells were seeded in six-well plates at a density of 1 × 106/well and grown 
to 70–80% of confluence with standard medium (DMEM-High Glucose). Cells were treated with vehicle (0.1% 
DMSO) or test compounds (i.e. 10 μM Memantine or Memit, and 1 μM Rapamycin) and incubated at 37 °C for 4 
and 24 h. After washing with ice-cold PBS cells were lysed and proteins (30–40 μg) were separated on Criterion 
TGXTM gel (4–20%) and transferred to Immuno-PVDF membrane (Bio-Rad, Milan, Italy). The membranes 
were probed overnight at 4 °C with primary antibodies [1:1000, LC3A/B; p62; mTOR, p-mTOR; Akt, p-Akt(Ser 
473); β-actin, Cell Signaling]. The primary antibodies were detected using appropriate secondary antibody. The 
peroxidase was detected using a chemiluminescent substrate (ECL, Perkin Elmer). Immunoreactive bands were 
quantified performing a densitometric analysis with Image Lab Software (Bio-Rad, Milan, Italy) and normalized 
to β-actin.
[3H]MK-801 Binding Assay. Crude synaptic membranes were prepared from the cerebral cortex of 
Sprague–Dawley rats38. Animals used procedures complied with NIH publication n° 80–23 revised in 1996 and 
approved by the Animals Care Commettee of the University of Pisa in compliance with the Directive 2010/63/
EU on animal welfare. The pellets were stored at −80 °C for at least 24 h, and washed three more times with Tris–
HEPES buffer (Tris 4.5 mM, HEPES 5 mM, pH 7.4) to remove the endogenous amino acids before the binding 
assay38.
In the binding assay, 50 μL of membrane preparation (40–50 μg protein), and 10 μL of compound were mixed 
at 25 °C in the presence of 50 µM L-glutamate (10 μM) and 50 μL of glycine (10 μM). Then, 50 µl of [3H]MK-801 
(final concentration 3 nM) were added to the preparation. Tris–HEPES buffer was added to a final volume of 
0.5 mL38. Following incubation time of 2 h at 25 °C, binding was terminated by rapid filtration. Radioactivity 
was measured using a PerkinElmer liquid scintillation counter. Nonspecific binding was determined in the pres-
ence of unlabeled 100 μM MK-801. The dissociation constant (Kd) of [3H]MK-801 in rat cortex membranes was 
4.0 nM. For compound activity determination, aliquots of membrane pellets were incubated with different ligand 
concentrations of Memit or Memantine (10 nM-10 µM) in the absence or presence of 4 mM Cysteine for 30 min, 
and then incubated with 3 nM [3H]MK-801 for 2 h at 25 °C. Samples were then filtered, and the radioactivity was 
counted.
Thioflavin T fluorescence assay. The ThT stock solution was prepared by adding 8 mg ThT to 10 mL phos-
phate buffer (10 mM phosphate, 150 mM NaCl, pH 7.0) and filtered through a 0.2 μm syringe filter. This stock 
solution should be stored in the dark and is stable for about one week. On the day of the analysis, the stock 
solution was diluted into PBS to obtain the concentration of 10 µM. The Aβ1–42 oligomers were prepared by dilut-
ing the stock solution in PBS and the dilution was shaked for 48 hours at 37 °C. The cells were seeded in black 
96-multiwell plate (3000 c/w) and treated with the compounds Memit or Memantine (10 µM) for 24 h. Following 
incubation, the samples were washed and incubated with Aβ1–42 oligomers for 24 h. After this time, 200 µl of ThT 
10 µM were added to each well in the dark. The ThT fluorescence intensity of each sample was recorded every 
5 min using a spectrophotometer by excitation at 355 nm and emission 535 nm.
Determination of H2s release by amperometric assay. The characterization of the potential 
H2S-generating properties of Memit has been carried out by an amperometric approach, through the Apollo-4000 
free radical analyzer (WPI) detector and H2S-selective mini-electrodes. 6 different recordings have been carried 
out at RT. Following the manufacturer’s instructions, a “PBS buffer 10x” was prepared (NaH2PO4•H2O 1.28 g, 
Na2HPO4•12H2O 5.97 g, NaCl 43.88 g in 500 ml H2O) and stocked at 4 °C. Immediately before the experiments, 
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the “PBS buffer 10x” was diluted using distilled water (1:10) to obtain the assay buffer and the pH adjusted to 
7.4. The H2S-selective mini-electrode was equilibrated in 10 ml of the assay buffer, until the recovery of a stable 
baseline. Then, 100 µL of a DMSO solution of the tested H2S-releasing compounds (Memit and positive drug 
GYY4137) was added, at the final concentration of 1 mM; the final concentration of DMSO in the assay buffer 
was 1%. The generation of H2S was observed for 20 min. Preliminary experiments demonstrated that DMSO 1% 
did not produce any interference on the amperometric recording. When required by the experimental protocol, 
L-Cysteine (final concentration 4 mM) was added 10 min before the addition of tested compounds. L-Cysteine 
alone did not produce any amperometric response. The correct relationship between the amperometric currents 
(recorded in pA) and the corresponding concentrations of H2S was previously determined by suitable calibration 
curves, which were obtained by the use of the H2S donor NaHS (1–3–5–10 μM) at pH 4.0. The curves relative to 
the progressive increase of H2S vs time, following the incubation of the tested compounds, were analysed follow-
ing the same procedure previously described29.
statistical analysis. The data were analysed and elaborated by Graph-Pad Prism 6.0 (GraphPad Software 
Inc., San Diego, CA, USA). All data are presented as the means ± SEM. Statistical analysis was performed by 
one-way analysis of variance (ANOVA), followed by Student–Newman–Keuls multiple comparison post hoc test 
or by Bonferroni’s corrected t-test for post-hoc pair-wise comparisons.
Results
Design and synthesis. Memit was developed as a novel NMDAR antagonist analogue of memantine pro-
vided of H2S-releasing properties. This new compound was efficiently synthesized by replacing the amine func-
tionality of memantine with an isothiocyanate group through reaction with thiophosgene in heterogeneous phase 
(NaHCO3 6%: DCM 1:1).
evaluation of Memit H2s-releasing properties via Amperometric assay. As previously described29, 
a real-time determination of the H2S release was achieved by using a H2S-selective minielectrode incubating 
reference H2S donor (GYY4137) or Memit in the presence or in absence of L-Cysteine. As shown in Fig. 2, in the 
absence of L-Cys the H2S generation from both compounds was almost negligible, whereas after pre-incubation 
with L-Cys a time-dependent increasing generation of H2S was observed.
Memit induces neuroprotection in human neuronal cell.  Neuronal-like cells, obtained from 
H9-derived human neural stem cells (NSCs), were incubated with an inflammatory cocktail (lLPS plusTNF-α) in 
order to mimic in vitro neuroinflammation39. The effects of Memit (10 μM) and native drug memantine (10 μM) 
under physiological conditions and under inflammatory stress exposure were investigated by cellular viability 
experiments (Fig. 3A). The compounds did not alter cellular proliferation “per se” (data not shown). As expected, 
the inflammatory mixture significantly affected the proliferation of neuronal-like cells. Pre-treatment for 24 or 
72 h of neuronal-like cells with the selected compounds significantly counteracted the decrease in cell prolifer-
ation elicited by the inflammatory insult. These results suggest that the new compound exerts neuro-protective 
effects in an experimental model of inflammation.
Memit reduces Ros production. To investigate the scavenger properties of memit, ROS levels were meas-
ured in neuronal-like cells under inflammatory conditions. Figure 3B shows that challenging neuronal-like cells 
with LPS-TNF-α significantly enhanced ROS accumulation. Pre-treatment with compound memit or with the 
native drug for 24 h almost completely counteracted inflammation-mediated ROS accumulation, thus suggesting 
that both compounds are able to prevent ROS accumulation.
Memit inhibits Aβ(1-40) self-induced aggregation. Accumulation of extracellular deposits of 
β-amyloid and abundant neurofibrillary tangles in the brain are correlated with neuron loss and progressive 
dementia15. Therefore, in order to evaluate the influence of memit on amyloid fibrils, a Th-T fluorescence 
assay was performed using NaHS as positive control15,16,40. Memit and Memantine were tested at 10 µM con-
centration; the results are reported in Fig. 4. As expected, Aβ1-42 significantly enhanced ThT-related fluores-
cence (165.5 ± 26.5% versus control). All the tested compounds exerted a significant inhibition of ThT-related 
Figure 2. Curves describe the increase of H2S concentration, with respect to time, following the incubation of 
GYY4137 (1 mM) and the test compound Memit (1 mM) in the assay buffer, in the absence (white symbol) or in 
the presence of L-cysteine (black symbol). The vertical bars indicate the SEM.
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fluorescence, thus indicating inhibition of Aβ1-42 self-aggregation. In particular Memit induced an Aβ1-42 
self-aggregation inhibition comparable to its progenitor Memantine.
Memit induces autophagy in U-87MG cell line. Autophagy (ATG) is a complex and finely regulated 
pathway, essential for the correct cellular physiology as it is involved in the degradation of long-lived cytoplasmic 
proteins, protein complexes, or damaged organelles. Impairments of the autophagic process are associated with 
several neurodegenerative disorders41, it is thus possible that the induction of ATG may be exploited as a strat-
egy to assist neuronal survival. The mammalian target of Rapamycin (m-TOR) is an evolutionarily conserved 
serine-threonine kinase that is known to play a major role in the modulation of ATG42,43. Therefore, to explore 
the neuroprotective potential of Memit and Memantine we decided to evaluate their ability to induce ATG in 
U-87MG cells, a human glioblastoma cell line characterized by a weak ATG machinery due to the upregulation 
of m-TOR44–46. Expression of protein indicators of autophagy, such as LC3-II47, p6248 and m-TOR, was detected 
Figure 3. (A) Effect of Memit and memantine treatments on an experimental model of neuroinflammation. 
The cells were challenged with Memit or memantine (10 μM) for 24 h or 72 h, and then treated LPS plus TNF-α 
for an additional 16 h. Cell proliferation was measured by MTS assay. The data are expressed as percentages 
relative to untreated cells (control), which were set at 100% (mean ± SEM, N = 3). (B) The cells were treated 
as in A. After treatment, ROS levels were quantified as described in the experimental section. The data are 
expressed as percentages relative to untreated cells (control), which were set at 100% (mean ± SEM, N = 3). 
**p < 0.01, ***p < 0.001 vs control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs cells treated with LPS/TNF-α.
Figure 4. Effect of the anti-amyloidogenic compounds, Memit and memantine, on amyloid oligomers 
formation. The cells were pre-treated with Memit, Memantine or NaHS (10 µM) for 24 h. Following incubation 
time, cells were washed and incubated with Aβ1-42 oligomers for 24 h. Following incubation, 200 µl of ThT 10 
µM were added to each well in the dark. The ThT fluorescence intensity of each sample was recorded every 5 
min using a spectrophotometer by excitation at 355 nm and emission 535 nm. Values represent mean ± SEM; 
*p < 0.05 vs Aβ1-42.
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by western blotting, using Rapamycin as a positive control. As shown in Fig. 5 a significant up-regulation of 
LC3II expression was observed after 4 h treatment with 10 μM Memit or Memantine (Fig. 5A), and also remained 
almost unchanged until 24 h treatment (Fig. 5B), suggesting that both Memit and Memantine are able to stim-
ulate the ATG flux. Consistently, after 4 h treatment parallel decreased expressions of p62, which is degraded 
during autophagy, and p-mTOR were observed (Fig. 5C,D). Next, we decided to address whether the observed 
induction of autophagy in U-87MG cells caused by treatment with 10 μM Memit or Memantine was accom-
plished via inhibition of the survival PI3K/Akt/mTOR pathway49. To this end, we analyzed the phosphorylation 
status of Akt in U-87MG cells treated with test compounds. As shown in Fig. 5E, 4 h treatment with Memit 
and Memantine (10 μM) resulted also in a significant reduction of the phosphorylation levels of Akt-Ser 473 
(*P < 0.05, **P < 0.01, versus vehicle treated cells), suggesting that, similarly to Rapamycin, both compounds 
may induce autophagy through the inhibition of the mTOR phosphorylation by the PI3K/AKT/mTOR pathway 
(full length Western blots for Fig. 5F are shown in Supplementary Fig. S1). In addition, cellular viability was deter-
mined using the MTT colorimetric assay. No significant alterations of cell viability were observed in U-87MG 
cells treated for 24 h with (10 μM) test compounds, as compared to vehicle (0.1% DMSO) (Fig. 6).
evaluation of Memit binding activity on NMDAR. Memit was tested to assess its ability to inhibit 
native-target activity (i.e. NMDAR). Binding to NMDAR was assessed using a radioligand assay on cortex mem-
branes based on the displacement of [3H]MK-80138, in the presence or absence of Cys (Table 1). Interestingly, 
while Memantine showed a significant displacement of [3H]MK-801 both in presence or in absence of Cys 
(Ki = 954.8 ± 74.2 nM and 328.8 ± 10.9 nM respectively), our H2S donor compound revealed a significant activ-
ity only in the presence of an organic source of H2S (Fig. 7 and Table 1). Importantly, the Ki value for memit 
(458.4 ± 77.7 nM) was comparable to that obtained for Memantine. These data demonstrate that memit could be 
considered a pro-drug of Memantine, released in the presence of Cys, and that the chemical modification did not 
alter the compound ability to bind NMDA.
Of note, Memit itself increased significantly its affinity for NMDA receptor in the presence of Cys (Fig. 7, 
Table 1), suggesting that Cys is involved in the regulation of the receptor affinity/functionality. Consistent with 
our hypothesis, crucial cysteine residues have been suggested to be involved in the modulation of NMDA protein 
Figure 5. Western blot quantification of LC3II/LC3I ratio, p62, mTOR and Akt as hallmarks of the degree 
of ATG activation in U87MG cells. Memantine (10 mM), Memit (10 mM) and Rapamycin (1 mM) induced 
increased LC3II/LC3I ratio at 4h (A) and 24h (B); a significant p62 degradation (C) and decreased p-mTOR/
mTOR ratio (D) and pAkt/Akt ratio (E). Results represent mean ± SEM of three different gels. *p < 0.05,  
**p < 0.01, ***p < 0.001 versus vehicle treated cells (Control). Representative western blots are shown in  
Panel F.
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activity and signaling events via other reactions of thiol groups50. In particular, the presence of cysteine in the 
binding buffer could involve reactions that affect ligand binding allosterically, as can be also observed by the Ki 
values of reference drug in the presence and in absence of Cys50.
Memit protects neuronal-like cells and microglia from Aβ(1-42) induced injury. Several studies 
have proved that H2S and NMDA ligands have protective effects on Aβ-induced cellular injury15,16. On this basis, 
the effect of Memit on injured neurons was assessed. As expected, oligomeric Aβ caused a significant reduction of 
neuronal viability (Fig. 8, panel A). When cells were pre-challenged with Memit, a marked cyto-protective effect 
was observed (Fig. 8, panel A). Similar results were obtained probing cells with Memantine (Fig. 8, panel A).
Microglia, together with astrocytes, forms the main active immune defense of the CNS. During the inflamma-
tion process, induction of NF-κB occurs, accompanied by a release of inflammatory mediators such as TNF-α, 
IL-6 and nitrite ions. Notably, also levels of CBS and H2S result down-regulated51,52. Consistently, to further deter-
mine the neuroprotection elicited by our hybrid, we decided to evaluate effects of Memit and Memantine on rat 
microglia cells. Cells were pretreated with the two compounds (10 µM concentration) followed by incubating 
Aβ1–42 oligomers. As depicted in Fig. 8 (panel B), pre-treatment with Memit and Memantine completely restored 
Figure 6. Cell viability assay. MTT assay showing U-87MG cells viability after 24 h treatment with tested 
compounds. Results are expressed as the mean ± SEM of twelve biological replicates.
Compound Ki, nM (−Cys)a
Ki, nM (+Cys 4 mM, 
30 min)a
Memit 28.0%b 458.4 ± 77.7
Memantine 954.8 ± 74.2 328.8 ± 10.9
Table 1. Displacement of specific [3H]MK-801 binding in rat cortex membranes in the absence or presence of 
cysteine (Cys). Data are reported as the means ± S.E.M. of three different experiments (performed in duplicate). 
aThe Ki values are means ± SEM derived from an iterative curve-fitting procedure (Prism program, GraphPad, 
San Diego, CA). bPercentage of inhibition is reported for Memit in the absence of Cys.
Figure 7. Displacement of specific [3H]MK-801 binding in rat cortex membranes in the absence or presence of 
cysteine (Cys). Rat cortex membranes were incubated with the indicated compounds and [3H]MK-801, in the 
absence or presence of Cys, Data are reported as percentage of radioligand specific binding and are the means ± 
S.E.M. of three different experiments (performed in duplicate).
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cell proliferation. These data demonstrate that the compounds can protect both neuronal cells and microglia from 
Aβ-induced injury.
Discussion
The goal of the present work was to develop a new and improved molecule for the treatment of neurodegener-
ation by modifying the structure of a well-established drug that is already approved for therapeutic use. Thus, 
starting from memantine, a compound currently prescribed for the treatment of moderate-to-severe Alzheimer’s 
disease, we created a new chemical entity, named memit, by introducing an isothiocyanate moiety capable of 
releasing H2S into its scaffold.
Although the pharmacological profile of memantine has been extensively studied (moderate affinity, uncom-
petitive, voltage-dependent, NMDA receptor antagonist that exhibits fast on/off kinetics53), the conjunction with 
an H2S-donor moiety creates a new hybrid molecule whose properties need to be fully investigated. Putatively 
such a molecule should exert neuroprotective and anti-inflammatory effects through both hydrogen sulphide- 
and NMDA-mediated mechanisms. This could result in a delaying of the neurodegeneration process.
Therefore, our initial studies were directed to assess whether memit still retains the pharmacological profile 
of the “native drug”, while also being a source for H2S in the CNS. To evaluate its H2S donor properties we used 
an amperometric approach29, which provides a real-time determination of H2S-release, either in the absence 
or in the presence of an organic thiol, such as L-cysteine. The results of the amperometric analysis on memit 
showed a prolonged and persisting L-cysteine mediated release, similar to that exhibited by the reference slow 
H2S-releasing agent GYY4137, a phosphinodithioate derivative.
Next, we investigated the neuroprotective activity of memit in human neuronal-like cells and in rat microglia 
cells, with the former representing the main active immune defense of the CNS. In neuronal cells, the neuropro-
tection was evaluated following an LPS-TNFα insult, known to induce oxidative stress and consequently apopto-
sis and cell death. The new drug demonstrated to protect cells from both oxidative stress and cytotoxicity induced 
by LPS-TNFα. The observed effects can be attributed to both NMDA binding and H2S release. Indeed, hydrogen 
sulfide has been proven to attenuate neural injury and cytokine release in rats54 and memantine has been shown 
to mitigate colchicine-induced inflammation in the hippocampus55.
In addition, Memit was able to reduce the Aβ(1-42) self-induced aggregation, with effects comparable to 
those of its progenitor memantine. Accordingly, memit and the native drug were also able to reduce Aβ 
oligomers-induced damage in rat microglia cells. Moreover, the observed reduction in Aβ accumulation elicited 
by Memit was shown to protect neuronal cells from the peptide-induced toxicity.
Consistent with our data, an over activation of NMDA receptor has been linked to abnormal Aβ deposition 
in AD and memantine has been demonstrated to decrease Aβ secretion in human cells or transgenic mice56,57.
Interestingly, H2S has been also proven to inhibit protein fibrillation of Aβ peptides by forming trisulfide 
bridges58 and therefore it may contribute to Memit-elicited properties.
Figure 8. Neuronal-like cells (panel A) or rat microglia cells (panel B) were pre-treated with Memit or 
Memantine (10 μM) for 24 h. After washing, the cells were challenged with Aβ1-42 for 24 h. At the end of 
treatments, cell proliferation was measured by MTS assay. The data are expressed as percentages relative to 
untreated cells (control), which were set at 100% (mean ± SEM, N=3) *p<0.05 vs control; #p<0.05 vs cells 
treated with Aβ1-42.
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The observed cytoprotection from Aβ-induced toxicity was then tested in microglia cells. Recent evidences 
have highlighted the pivotal role of these cells in different neuropathologies, including AD59. Notably, pharmaco-
logical studies suggest that promoting microglia polarization plays a key role in maintaining tissue homeostasis 
through different mechanisms including the suppression of inflammation59. In our hand, both memit and the 
native drug were also able to reduce Aβ oligomers-induced damage in rat microglia cells, suggesting the two 
drugs as promising protective agents for non-neuronal cells too.
Moreover, since a large body of evidence underlies the existence of a correlation between neurodegeneration 
and altered autophagic flux60, we also decided to investigate the ability of memit and memantine to induce auto-
phagy in U87-MG cells. Our western blot analysis revealed that both compounds were able to significantly affect 
the expression of common autophagy markers such as LC3II, p62, mTOR and Akt, suggesting that autophagy 
could be an additional mechanism to strengthen their efficacy as neuroprotective drugs. These data are of par-
ticular relevance considering the role of AKT/mTOR pathway in the modulation of autophagy and the clearance 
of protein oligomers in neurodegenerative diseases49.
Finally, we also tested the ability of memit to bind to the NMDA receptor, the main target of memantine. 
Interestingly, we found that memit displayed an affinity comparable to that of the native drug only when cysteine 
was present in the assay medium, while no binding was observed in the absence of cysteine. These observa-
tions suggest that memit behaves as a prodrug, and that the binding is due to the production of memantine. 
In this sense, it has to be mentioned the reported facilitating effects of hydrogen-sulfide on NMDA recep-
tors61,62. Nevertheless, the functional consequences of H2S-mediated NMDA receptor activation in neurons 
and stem cells is not strictly linked to neurotoxicity. For example, these facilitating actions are age- and recep-
tor subunit-specific61 and can finally promote synaptic plasticity. Furthermore, H2S has been demonstrated to 
enhance NMDA receptor-mediated currents and facilitate the induction of hippocampal long-term potentiation 
(LTP)63. Finally, activation of NMDA receptors increases proliferation and differentiation of hippocampal neural 
progenitor cells64 and thus does not show toxic effects on differentiated cells.
Further studies will be needed to elucidate changes in NMDA receptor functionality that can be mediated by 
Memit-released hydrogen sulfide.
Conclusion
Unfortunately, to date the etiopathology of neurodegeneration is still not well understood and the therapies that 
are currently available lack in efficacy, as they are unable to completely block neuronal damage. Consequently, 
there is an enormous need for new therapeutic tools that are at least capable of slowing down the progression 
of the pathology. The work we presented here describes the synthesis and the preliminary in vitro evaluation of 
an innovative multi-functional prodrug. To the best of our knowledge, memit is the first compound capable of 
producing H2S in the CNS that was designed starting from the well-known drug memantine. The new compound 
we have developed has the potential of restoring H2S levels in the CNS and, like memantine, has the ability of 
inducing autophagy, thus eliciting neuroprotective effects. However, further in vivo investigations will be neces-
sary to fully appreciate the synergistic or cumulative effects due to the H2S-releasing moiety and the native drug.
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